UNITED STATES


UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): March 25, 2014


IGI LABORATORIES, INC.


(Exact name of registrant as specified in its charter)


Delaware

001-08568

01-0355758

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

 

 

105 Lincoln Avenue
Buena, New Jersey

 

08310

(Address of principal executive offices)

 

(Zip Code)


Registrant’s telephone number, including area code: (856) 697-1441


Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[   ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

[   ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

[   ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

[   ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(b)

On March 25, 2014, Joyce Erony, a director and the chairperson of IGI Laboratories, Inc.’s (the “Company’s”) board of directors, advised the Company that she will not stand for re-election as a director at the Company’s annual meeting to be held on May 27, 2014.


On March 28, 2014, Michael B. Hemric advised the Company that he will be resigning as a director of the Company’s Board of Directors effective April 1, 2014.







SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

IGI LABORATORIES, INC.

 

 

Date: March 31, 2014

By:

/s/ Jenniffer Collins

 

Name:

Jenniffer Collins

 

Title:

Chief Financial Officer